Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? PetVivo’s new study shows that a single intra-articular Spryng injection with OsteoCushion technology can improve pain and function in dogs with stifle osteoarthritis and suspected cranial cruciate disease. While the authors call for larger studies with obj...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? Wuffes’ PetSmart rollout is a big distribution milestone that moves it from DTC success into mainstream retail scale, giving the brand national shelf visibility, stronger consumer trust, and access to PetSmart’s 1,300+ U.S. stores plus its e-commerce traffi...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Quick Takeaways: Why It Matters? AKS-699 is being positioned as a long-interval, owner-friendly alternative to monthly IL‑31 biologics like Cytopoint in canine atopic dermatitis. The favorable efficacy and tolerability profile in preclinical work (only mild, transient injection-site r...
Quick Takeaways: Why It Matters? Pawsible Ventures is positioning itself as the “infrastructure VC” for pet health, and this eight‑company debut cohort shows what that means in practice: e‑prescribing rails (VetHubRx), AI clinic copilots (NxVET, PupPilot), preventive‑...
Revenue: $5.4M Founded Year: 1982 Market Cap: 54.85M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ ImmuCell is an animal health company that aims towards the development, manufacturing, and marketing of scientifically-proven products that improve health and...
